Oklahoma Law Expanding 340B Drug Access Faces Legal Challenge
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Oklahoma lawmakers enacted the 340B Nondiscrimination Act last year to prevent pharmaceutical manufacturers from limiting delivery options for patients receiving discounted drugs through the federal 340B Drug Pricing Program. Pharmaceutical companies are currently challenging this state law in the 10th Circuit. A U.S. District Judge previously granted a preliminary injunction blocking the law.
From oklahomacitysun.com
Why it matters
The 340B program, established in 1992, allows covered healthcare providers to order discounted medications from manufacturers and bill insurers full price. The legal dispute questions the scope of this program and how discounted drugs are delivered to patients.
From oklahomacitysun.com
Who's involved
- AbbVieA pharmaceutical company named as a litigant challenging the state law's impact on 340B pricing and distribution.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
AbbVie could face changes in revenue or costs related to drug pricing and distribution if the state law is altered.
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company